Statins, targeting HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the mevalonate pathway, widely used for cardiovascular diseases, have demonstrated anti-tumor effects across multiple cancers. Here, HMGCR is linked to neoplasm.